Pulmonary neuroendocrine tumors in the new WHO 2015 classification: Start of breaking new grounds?;Pulmonale neuroendokrine Tumoren in der neuen WHO-Klassifikation 2015: Beginn eines Aufbruchs zu „neuen Ufern“?

Pathologe

Volumn 36, Issue 3, 2015, Pages 283-292

  Schnabel, P A ^a   Junker, K ^b  

^a SAARLAND UNIVERSITY   (Germany)

^b KLINIKUM BREMEN MITTE   (Germany)

Author keywords

Atypical carcinoid; Large cell neuroendocrine lung cancer; Small cell lung cancer; Typical carcinoid; WHO classification

Indexed keywords

CD56 ANTIGEN; CHROMOGRANIN A; NCAM1 PROTEIN, HUMAN; SYNAPTOPHYSIN; TUMOR MARKER;

BIOPSY; CANCER GRADING; CARCINOID; CLASSIFICATION; DIFFERENTIAL DIAGNOSIS; HUMAN; LARGE CELL CARCINOMA; LUNG; LUNG TUMOR; NEUROECTODERM TUMOR; NEUROENDOCRINE TUMOR; PATHOLOGY; SMALL CELL CARCINOMA; WORLD HEALTH ORGANIZATION;

ANTIGENS, CD56; BIOMARKERS, TUMOR; BIOPSY; CARCINOID TUMOR; CARCINOMA, LARGE CELL; CARCINOMA, SMALL CELL; CHROMOGRANIN A; DIAGNOSIS, DIFFERENTIAL; HUMANS; LUNG; LUNG NEOPLASMS; NEOPLASM GRADING; NEUROECTODERMAL TUMORS, PRIMITIVE; NEUROENDOCRINE TUMORS; SYNAPTOPHYSIN; WORLD HEALTH ORGANIZATION;

EID: 84929958713     PISSN: 01728113     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00292-015-0030-2     Document Type: Article

References (51)

1. Ampollini L, Carbognani P, Rusca M, Bobbio A (2010) Resection of giant typical carcinoid tumor with cardiopulmonary bypass support. Thorac Cardiov Surg 58:494–502
2. Beasley MB, Brambilla E, Chirieac LR, Austin JHM, Devesa SS, Hasleton P, Jett J, Marchevsky AM, Nicholson S, Papotti M, Pelosi G, Rami-Porta R, Scagliotti G, Thunnissen E, Travis WD, van Schil P, Yang P (2015) Carcinoid tumor. In: Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG (Hrsg) WHO Classification of tumors of the lung, pleura, thymus and heart. IARC Press, Lyon, S 73–77
3. Bohle RM, Kim YJ, Schnabel PA (2015) Lungentumoren – Lehrserie Nr. 221, Internationale Akademie für Pathologie, Deutsche Abteilung e. V.
4. Brambilla E, Beasley MB, Austin JHM, Capelozzi VL, Chirieac LR, Devesa SS, Frank GA, Gazdar A, Ishikawa Y, Jen J, Jett J, Marchevsky AM, Nicholson S, Pelosi G, Powell CA, Rami-Porta R, Scagliotti G, Thunissen E, Travis WD, van Schil P, Yang P (2015) Small cell carcinoma. In: Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG (Hrsg) WHO classification of tumors of the lung, pleura, thymus and heart. IARC Press, Lyon, S 63–68
5. Brambilla E, Beasley MB, Chirieac LR, Austin JHM, Capelozzi VL Devesa SS, Gazdar A, Ishikawa Y, Jett J, Nicholson S, Pelosi G, Powell CA, Rami-Porta R, Riely G, Scagliotti G, Travis WD, van Schil P, Yang P, Yankelevitz D (2015) Large cell neuroendocrine carcinoma. In: Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG (Hrsg) WHO classification of tumors of the lung, pleura, thymus and heart. IARC Press, Lyon, S 69–72
6. Brokx HAP, Paul MA, Postmus PE, Sutedja TG (2015) Long-term follow-up after first-line bronchoscopic therapy in patients with bronchial carcinoids. Thorax. (Epüb ahead of print)
7. Collisson EA, Campbell JD, Brooks AN et al (2014) Comprehensive molecular profiling of lung adenocarcinoma. Cancer Genome Atlas Research Network. Nature 511:543–540
8. Diakatou E, Alexandri KI, Tsolakis AV, Kontogeorgos G, Chatzellis E, Leonti A, Kaltsas GA (2015) Somatostatin and dopamine receptor expression in neuroendocrine neoplasms; correlation of immunohistochemical findings with somatostatin receptor scintigraphy visual scores. Clin Endocrinol (Oxf.). doi:10.1111/cen.12775. vv
9. Dong HY, Liu W, Cohen P, Mahle CE, Zhang W (2005) B-cell specific activation protein encoded by the PAX-5 gene is commonly expressed in Merkel cell carcinoma and small cell carcinomas. Am J Surg Pathol 29:687–692
10. Fernandez-Cuesta L, Peifer M, Lu X, Sun R, Ozrtic L, Seidel D, Zander T, Leenders F, George J, Müller C, Dahmen I, Pinther B, Bosco G, Konrad K, Altmüller J, Nürnberg P, Achter V, Lang U, Schneider PM, Bogus M, Soltermann A, Brustugun OT, Helland A, Solberg S, Lund-Iversen M, Ansén S, Stoelben E, Wright GM, Russell P, Wainer Z, Solomon B, Field JK, Hyde R, Davies MPA, Heukamp LC, Petersen I, Perner S, Lovly CM, Cappuzzo F, Travis WD, Wolf J, Vingron M, Brambilla E, Haas SA, Buettner R, Thomas RK (2014) Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids. Nat Commun 5:3518. doi:10.1038/ncomms4518
11. Gazdar AF, Savage TK, Johnson JE, Berns A, Sage J, Linoilla RI, MacPherson D, McFadden DG, Farago A, Jacks T, Travis WD, Brambilla E (2015) The comparative pathology of genetically engineered mouse models for neuroendocrine carcinomas of the lung. J Thorac Oncol 10:553–564
12. Gosney JR, Austin JHM, Jett J, Nicholson AG, Nicholson S, Rami-Porta R, Travis WD, van Schil P (2015) Preinvasive leason – Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia. In: Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG (Hrsg) WHO Classification of tumors of the lung, pleura, thymus and heart. IARC Press, Lyon, S 78–79
13. Gottschling S, Jensen K, Herth FJF, Thomas M, Schnabel PA, Herpel E (2013) Lack of prognostic significance of neuroendocrine differentiation and stem cell antigen co-expression in resected early-stage non-small cell lung cancer. Anticancer Res 33:981–990
14. Grohé C (2014) Neuroendokrine Lungentumoren. Pneumologie 68:455–477
15. Hassan MM, Phan A, Li D, Dagohoy CG, Leary C, Yao JC (2008) Risk factors associated with neuroendocrine tumors: A U.S.-based case-control study. Int J Cancer 123:867–873
16. Helmbold P, Lahtz C, Herpel E, Schnabel PA, Dammann RH (2009) Frequent hypermethylation of RASSF1A tumour suppressor gene promoter and presence of Merkel cell polyomavirus in small cell lung cancer. Eur J Cancer 45:2207–2211
17. Huwer H, Kalweit G, Schäfer H, Eltze E (2011) Pulmonales Paragangliom: Fallbericht und Literaturübersicht. Pneumologie 65:742–744
18. Iyoda A, Jiang S-X, Travis WD, Kurouzu N, Ogawa F, Amano H, Sato Y, Rusch VW, Saegusa M, Satoh Y (2013) Clinicopathological features and the impact of the new TNM classification of malignant tumors in patients with pulmonary large cell neuroendocrine carcinoma. Mol Clin Oncol 1:437–443
19. Johney EC, Pfannschmidt J, Rieker RJ, Schnabel PA, Mechtersheimer G, Dienemann H (2006) Diffuse idiopathic pulmonary neuroendocrine cell hyperplasio and a typical carcinoid tumor. J Tharac Cardiovasc Surg 131:1207–1208
20. Junker K, Länger F, Schnabel PA (2013) Update Pneumopathologie – Bericht der AG Pneumopathologie der Deutschen Gesellschaft für Pathologie. Pathologe 34(Suppl 2):304–307
21. Kaemmerer D, Specht E, Sänger J, Wirtz RM, Sayeg M, Schulz S, Lupp A (2015) Somatostatin receptors in bronchopulmonary neuroendocrine neoplasms: new diagnostic, prognostic, and therapeutic markers. J Clin Endocrinol Metab 100:831–840
22. Kanteti R, Nallasura V, Loganathan S, Tretiakova M, Kroll T, Krishnaswamy S, Faoro L, Cagle P, Husain AN, Vokes EE, Lang D, Salgia R (2009) PAX5 is expressed in small cell lung cancer and positively regulates c-Met transcription. Lab Invest 89:301–314
23. Le Treut J, Sault MC, Lena H, Souquet PJ, Vergnenegre A, Le Caer H, Berard H, Boffa S, Monnet I, Damotte D, Chouaid C (2013) Multicentre phase II study of cisplatin-etoposide chemotherapy for advanced large-cell neuroendocrine lung carcinoma: the GFPC 0302 study. Ann Oncol 24:1548–1552
24. Mireskandari M, Abdirad A, Zhang Q, Dietel M, Petersen I (2013) Association of small foci of diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) with adenocarcinoma of the lung. Path Res Pract 209:578–584
25. Nenekidis I, Stathopoulos GT, Anagnostakou V, Kokkori A, Dedeilias P, Kokotsakis J, Argiriou M, Zisis C (2011) Atypical pulmonary carcinoid tumour in a 28-year-old nonsmoker with Prader-Willi syndrome. Eur Respir J 38:1230–1233
26. Peifer M, Fernández-Cuesta L, Sos ML et al (2012) Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet 44:1104–1110
27. Pelosi G, Rodriguez J, Viale G, Rosai J (2005) Typical and atypical pulmonary carcinoid tumor overdiagnosed as small-cell carcinoma on biopsy specimens: a major pitfall in the management of lung cancer patients. Am J Surg Pathol 29:179–187
28. Petersen I, Schnabel PA (2011) Neues zur Lungenpathologie. Bericht der Arbeitsgemeinschaft Pneumopathologie der Deutschen Gesellschaft für Pathologie. Pathologe 32 (Suppl 2):351–357
29. Righi L, Volante M, Tavaglione V, Billè A, Daniele L, Angusti T, Inzani F, Pelosi G, Rindi G, Papotti M (2010) Somatostatin receptor tissue distribution in lung neuroendocrine tumours: a clinicopathologic and immunohistochemical study of 218 ‚clinically aggressive‘ cases. Ann Oncol 21:548–555
30. Rindi R, Klersy C, Inzani F, Fellegara G, Ampolloni L, Ardizzoni A, Campanini N, Carbognani P, De Pas DM, Galetta D, Granone PL, Righi L, Rusca M, Spaggiari L, Tiseo M, Viale G, Volante M, Papotti M, Pelosi G (2014) Grading the neuroendocrine tumors of the lung: an evidence-based proposal. Endocr Relat Cancer. doi:10.1530/ERC-13-0246
31. Rossi G, Mengoli MC, Cavazza A, Nicoli D, Barbareschi M, Cantaloni C, Papotti M, Tironi A, Graziano P, Paci M, Stefani A, Migaldi M, Sartori G, Pelosi G (2014) Large cell carcinoma of the lung: clinically oriented classification integrating immunohistochemistry and molecular biology. Virchows Arch 464:61–68
32. Sachithanandan N, Harle RA, Burgess JR (2005) Bronchopulmonary carcinoid in multiple endocrine neoplasia type 1. Cancer 103:509–515
33. Schnabel PA, Junker K (2014) Neuroendokrine Tumoren der Lunge – Vom kleinzelligen Lungenkarzinom bis zur diffusen idiopathischen pulmonalen neuroendokrinen Zellhyperplasie. Pathologe 35:557–564
34. Schnabel PA, Petersen I, Junker K (2012) Neueste Aktivitäten in der Pneumopathologie -Bericht der Arbeitgemeinschaft Pneumopathologie der Deutschen Gesellschaft für Pathologie. Pathologe 33(Suppl 2):351–354
35. Schnabel PA, Veith C, Zaharia C, Langer F, Seidel RM, Wehler TC, Bohle RM (2015) Co-occurrence of DIPNECH and of meningotheliosis with a pulmonary adenocarcinoma (pADC) in one lung lobe – Consequences for sampling. (Zur Publikation eingereicht)
36. Seidel D, Zander T, Heukamp LC et al (2013) A genomics-based classification of human lung tumors – Clinical Lung Cancer Genome Project (CLCGP); Network Genomic Medicine (NGM). Sci Transl Med 5(209):209ra153
37. Sica G, Vazquez MF, Altorki N, Port J, Lee PC, Liu Y, Hyjek E, Saqi A (2008) PAX-5 expression in pulmonary neuroendocrine neoplasms. Am J Clin Pathol 129:556–562
38. Song J, Li M, Tretiakova M, Salgia R, Cagle PT, Husain AN (2010) Expression patterns of PAX5, c-MET and Paxillin in neuroendocrine tumors of the lung. Arch Pathol Lab Med 134:1702–1705
39. Sterlacci W, Fiegl M, Hilbe W, Auberger J, Mikuz G, Tzankov A (2009) Clinical relevance of neuroendocrine differentiation in non-small cell lung cancer assessed by immunohistochemistry: a retrospective study on 405 surgically resected cases. Virchows Arch 455:125–132
40. Travis WD, Brambilla E, Müller-Hermelink HK et al (2004) Tumors of the Lung, Pleura Thymus and Heart, World Health Organization classification of tumors. Pathology and genetics. IARC Press, Lyon
41. Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG (2015) WHO Classification of tumors of the lung, pleura, thymus and heart. IARC Press, Lyon
42. Travis WD, Brambilla E, Noguchi M et al (2011) International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 6:244–285
43. Thunissen E, Kerr KM, Herth FJF, Lantuejoul S, Papotti M, Rintoul RC, Rossi G, Skov BG, Weynand B, Bubendorf L, Katrien G, Johansson L, López-Rios F, Ninane V, Olzewski W, Popper H, Jaume S, Schnabel PA, Thiberville L, Laenger F (2012) The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group. Lung Cancer 76:1–18
44. Volante M, Gatti G, Papotti M (2015) Classification of lung neuroendocrine tumors: lights and shadows. Endocrine. (Epub ahead of print)
45. Walter RF, Mairinger FD, Werner R, Ting S, Vollbrecht C, Theegarten D, Christoph DC, Zarogoulidis K, Werner KW, Zarogoulidis P, Wohlschläger J (2015) SOX4, SOX11 and PAX6 mRNA expression was identified as a (prognostic) marker for the aggressiveness of neuroendocrine tumors of the lung by using next-generation expression analysis (NanoString). Future Oncol 7:1027–1036
46. Warth A, Endris V, Penzel R, Weichert W (2014) Molecular pathology of lung cancer. State of the art 2014. Pathologe 35:565–573
47. Warth A, Fink L, Fisseler-Eckhoff A, Jonigk, Keller M, Ott G, Rieker RJ, Sinn P, Söder S, Soltermann A, Willenbrock K, Weichert W, on behalf of the Pulmonary Pathology Working Group of the German Society of Pathology (2013) Interobserver agreement if proliferation index (Ki-67) outperforms mitotic count in pulmonary carcinoids. Virchows Arch 462:507–513
48. Warth A, Herpel E, Krysa S, Hoffmann H, Schnabel PA, Schirmacher P, Mechtersheimer G, Bläker H (2009) Chromosomal instability is more frequent in metastasized than in non-metastasized pulmonary carcinoids but is not a reliable predictor of metastatic potential. Exp Mol Med 41:349–353
49. Warth A, Herpel E, Schmähl A, Storz K, Schnabel PA (2008) Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) in association with an adenocarcinoma: a case report. J Medical Case Reprts 2:21–23
50. Warth A, Krysa S, Zahel T, Hoffmann H, Schirmacher P, Schnabel PA, Herpel E (2010) S100 protein positive sustentacular cells in pulmonary carcinoids and thoracic paragangliomas: differential diagnostic and prognostic evaluation. Pathologe 31:379–384
51. Zahel T, Krysa S, Herpel E, Stenzinger A, Goeppert B, Schirmacher P, Schnabel PA, Warth A (2012) Phenoptyping of pulmonary carcinoids and a Ki-67-based grading approach. Virchows Arch 460:299–308